UBS analyst Matthew Weston maintained a Hold rating on Novartis AG today and set a price target of CHF95.00. The company’s shares closed yesterday at CHF91.55.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Weston is a 4-star analyst with an average return of 6.4% and a 68.00% success rate. Weston covers the Healthcare sector, focusing on stocks such as Novartis AG, AstraZeneca, and Roche Holding AG.
In addition to UBS, Novartis AG also received a Hold from J.P. Morgan’s Richard Vosser in a report issued on July 18. However, yesterday, Barclays maintained a Sell rating on Novartis AG (Six Swiss: NOVN).
Based on Novartis AG’s latest earnings release for the quarter ending March 30, the company reported a quarterly revenue of CHF13.62 billion and a net profit of CHF3.61 billion. In comparison, last year the company earned a revenue of CHF12.12 billion and had a net profit of CHF2.69 billion
Read More on CH:NOVN:
- Amgen and Novartis’s Erenumab Study: A Potential Game-Changer in Pediatric Migraine Treatment
- Morning Movers: PepsiCo gains following second quarter results
- Novartis reports Q2 EPS core $2.42, consensus $2.37
- Novartis sees FY25 sales up high single digits
- Novartis initiating up to $10B share buyback to be completed by YE27